Prometheus_Biosciences_Logo.jpg
Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
August 11, 2022 16:00 ET | Prometheus Biosciences
- Both topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results expected concurrently in 4Q 2022 - - Bioavailability greater than 80% achieved upon completion of PRA023 subcutaneous bridging...